[{"id":"9455efaa-e977-4616-8644-72913019ad15","acronym":"","url":"https://clinicaltrials.gov/study/NCT04989387","created_at":"2021-08-04T13:52:52.724Z","updated_at":"2025-02-25T16:16:34.090Z","phase":"Phase 1","brief_title":"Study of INCA 0186 in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT04989387","lead_sponsor":"Incyte Corporation","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • INCB106385 • uprevstobart (INCA00186)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 10/04/2021","start_date":" 10/04/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-11-06"}]